Voyager Therapeutics (VYGR)

• Market cap: $234M
• 1 day: -1.17%
• 5 days: -6.01%
• 1 month: -14.75%
• 3 months: 24.12%
• 6 months: 29.85%
• Year to date: -29.31%
• 1 year: -42.03%
• 5 years: -61.57%
• 10 years: -76.23%
• Sector: Healthcare
• Industry: Biotechnology

About: Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

Employees: 172